
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES171
The same RCT291 reported significant differences between the groups, in favour of atorvastatin 80 mg, for the secondary outcomes of time to cerebrovascular event (p<0.037) and time to CV event (p<0.044). Level 1++

[@Shepherd_2006]

